Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93


[Subclassification of follicular carcinoma (WHO 2017) : Are all subtypes malignant?]

Schad A.

Pathologe. 2019 Nov 14. doi: 10.1007/s00292-019-00707-5. [Epub ahead of print] German. No abstract available.


Correction to: Retinal pathology in experimental optic neuritis is characterized by retrograde degeneration and gliosis.

Manogaran P, Samardzija M, Schad AN, Wicki CA, Walker-Egger C, Rudin M, Grimm C, Schippling S.

Acta Neuropathol Commun. 2019 Oct 18;7(1):157. doi: 10.1186/s40478-019-0825-0.


Prognostic Assessment of Non-functioning Neuroendocrine Pancreatic Neoplasms as a Basis for Risk-Adapted Resection Strategies.

Watzka FM, Meyer F, Staubitz JI, Fottner C, Schad A, Lang H, Musholt TJ.

World J Surg. 2019 Oct 11. doi: 10.1007/s00268-019-05220-7. [Epub ahead of print]


Random allogeneic blood transfusion in pigs: characterisation of a novel experimental model.

Ziebart A, Schaefer MM, Thomas R, Kamuf J, Garcia-Bardon A, Möllmann C, Ruemmler R, Heid F, Schad A, Hartmann EK.

PeerJ. 2019 Aug 16;7:e7439. doi: 10.7717/peerj.7439. eCollection 2019.


ANKRD26-RET - A novel gene fusion involving RET in papillary thyroid carcinoma.

Staubitz JI, Musholt TJ, Schad A, Springer E, Lang H, Rajalingam K, Roth W, Hartmann N.

Cancer Genet. 2019 Oct;238:10-17. doi: 10.1016/j.cancergen.2019.07.002. Epub 2019 Jul 5.


Retinal pathology in experimental optic neuritis is characterized by retrograde degeneration and gliosis.

Manogaran P, Samardzija M, Schad AN, Wicki CA, Walker-Egger C, Rudin M, Grimm C, Schippling S.

Acta Neuropathol Commun. 2019 Jul 17;7(1):116. doi: 10.1186/s40478-019-0768-5. Erratum in: Acta Neuropathol Commun. 2019 Oct 18;7(1):157.


PD-L1 Expression and Immune Cell Infiltration in Gastroenteropancreatic (GEP) and Non-GEP Neuroendocrine Neoplasms With High Proliferative Activity.

Ferrata M, Schad A, Zimmer S, Musholt TJ, Bahr K, Kuenzel J, Becker S, Springer E, Roth W, Weber MM, Fottner C.

Front Oncol. 2019 May 7;9:343. doi: 10.3389/fonc.2019.00343. eCollection 2019.


Cirrhosis risk score of the donor organ predicts early fibrosis progression after liver transplantation.

Zimmermann A, Darstein F, Hoppe-Lotichius M, Toenges G, Lautem A, Abel F, Schad A, Mittler J, Vollmar J, Grimm D, Lang H, Galle PR, Zimmermann T, Schuppan D.

J Gastrointestin Liver Dis. 2019 Mar;28(1):53-61. doi: 10.15403/jgld.2014.1121.281.crr.


Expression and prognostic significance of insulin‑like growth factor-2 receptor in human hepatocellular carcinoma and the influence of transarterial chemoembolization.

Lautem A, Simon F, Hoppe-Lotichius M, Mittler J, Vollmar J, Schad A, Düber C, Galle PR, Otto G, Zimmermann T, Lang H.

Oncol Rep. 2019 Apr;41(4):2299-2310. doi: 10.3892/or.2019.6995. Epub 2019 Feb 1.


Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program.

Moehler M, Maderer A, Ehrlich A, Foerster F, Schad A, Nickolay T, Ruckes C, Weinmann A, Sivanathan V, Marquardt JU, Galle PR, Woerns M, Thomaidis T.

BMC Cancer. 2019 Jan 11;19(1):55. doi: 10.1186/s12885-018-5223-7.


Detection of RET rearrangements in papillary thyroid carcinoma using RT-PCR and FISH techniques - A molecular and clinical analysis.

Musholt TJ, Staubitz JI, Antonio Cámara RJ, Musholt PB, Humberg D, Springer E, Schad A.

Eur J Surg Oncol. 2019 Jun;45(6):1018-1024. doi: 10.1016/j.ejso.2018.11.009. Epub 2018 Nov 16.


Novel rearrangements involving the RET gene in papillary thyroid carcinoma.

Staubitz JI, Schad A, Springer E, Rajalingam K, Lang H, Roth W, Hartmann N, Musholt TJ.

Cancer Genet. 2019 Jan;230:13-20. doi: 10.1016/j.cancergen.2018.11.002. Epub 2018 Nov 13.


[Liver injury induced by immune checkpoint inhibitor-therapy : Example of an immune-mediated drug side effect].

Straub BK, Ridder DA, Schad A, Loquai C, Schattenberg JM.

Pathologe. 2018 Nov;39(6):556-562. doi: 10.1007/s00292-018-0519-6. Review. German.


Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071).

Moehler M, Schad A, Maderer A, Atasoy A, Mauer ME, Caballero C, Thomaidis T, John JMM, Lang I, Van Cutsem E, Freire J, Lutz MP, Roth A; EORTC Gastrointestinal Tract Cancer Group.

Cancer Chemother Pharmacol. 2018 Oct;82(4):733-739. doi: 10.1007/s00280-018-3667-8. Epub 2018 Aug 13.


Progression of transthyretin (TTR) amyloidosis in donors and recipients after domino liver transplantation-a prospective single-center cohort study.

Vollmar J, Schmid JC, Hoppe-Lotichius M, Barreiros AP, Azizi M, Emrich T, Geber C, Schad A, Weyer V, Otto G, Heise M, Mittler J, Birklein F, Lang H, Galle PR, Zimmermann T.

Transpl Int. 2018 Nov;31(11):1207-1215. doi: 10.1111/tri.13326. Epub 2018 Aug 28.


Loss of organic cation transporter 3 (Oct3) leads to enhanced proliferation and hepatocarcinogenesis.

Vollmar J, Lautem A, Closs E, Schuppan D, Kim YO, Grimm D, Marquardt JU, Fuchs P, Straub BK, Schad A, Gründemann D, Schattenberg JM, Gehrke N, Wörns MA, Baumgart J, Galle PR, Zimmermann T.

Oncotarget. 2017 Dec 18;8(70):115667-115680. doi: 10.18632/oncotarget.23372. eCollection 2017 Dec 29.


Targeted next-generation sequencing of cancer genes in poorly differentiated thyroid cancer.

Gerber TS, Schad A, Hartmann N, Springer E, Zechner U, Musholt TJ.

Endocr Connect. 2018 Jan;7(1):47-55. doi: 10.1530/EC-17-0290. Epub 2017 Nov 13.


Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells.

Thaler S, Schmidt M, Roβwag S, Thiede G, Schad A, Sleeman JP.

Oncotarget. 2017 Aug 14;8(42):72281-72301. doi: 10.18632/oncotarget.20261. eCollection 2017 Sep 22.


Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536.

Breitenbuecher F, von Pawel J, Sebastian M, Kortsik C, Ting S, Kasper S, Wohlschläger J, Worm K, Morresi-Hauf A, Schad A, Westerwick D, Wehler B, Werner M, Munzert G, Gaschler-Markefski B, Schmid KW, Schuler M.

Oncol Res Treat. 2017;40(7-8):435-439. doi: 10.1159/000475503. Epub 2017 Jun 20.


Detection of cellular senescence within human invasive breast carcinomas distinguishes different breast tumor subtypes.

Cotarelo CL, Schad A, Kirkpatrick CJ, Sleeman JP, Springer E, Schmidt M, Thaler S.

Oncotarget. 2016 Nov 15;7(46):74846-74859. doi: 10.18632/oncotarget.12432.


[Unusual dysphagia in IgG4-related disease].

Engelbarts M, Schad A, Matthias C.

HNO. 2017 Aug;65(8):680-683. doi: 10.1007/s00106-016-0205-z. German.


Physiologic Frailty in Nonelderly Hematopoietic Cell Transplantation Patients: Results From the Bone Marrow Transplant Survivor Study.

Arora M, Sun CL, Ness KK, Teh JB, Wu J, Francisco L, Armenian SH, Schad A, Namdar G, Bosworth A, Kuo L, Weisdorf DJ, Forman SJ, Bhatia S.

JAMA Oncol. 2016 Oct 1;2(10):1277-1286. doi: 10.1001/jamaoncol.2016.0855.


Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment.

Grimm D, Lieb J, Weyer V, Vollmar J, Darstein F, Lautem A, Hoppe-Lotichius M, Koch S, Schad A, Schattenberg JM, Wörns MA, Weinmann A, Galle PR, Zimmermann T.

BMC Cancer. 2016 Feb 12;16:94. doi: 10.1186/s12885-016-2150-3.


Surgical Treatment of NEN of Small Bowel: A Retrospective Analysis.

Watzka FM, Fottner C, Miederer M, Weber MM, Schad A, Lang H, Musholt TJ.

World J Surg. 2016 Mar;40(3):749-58. doi: 10.1007/s00268-016-3432-2.


Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir.

Bernuth S, Yagmur E, Schuppan D, Sprinzl MF, Zimmermann A, Schad A, Kittner JM, Weyer V, Knapstein J, Schattenberg JM, Wörns MA, Galle PR, Zimmermann T.

Dig Liver Dis. 2016 Mar;48(3):291-7. doi: 10.1016/j.dld.2015.09.015. Epub 2015 Oct 3.


Pulmonary effects of expiratory-assisted small-lumen ventilation during upper airway obstruction in pigs.

Ziebart A, Garcia-Bardon A, Kamuf J, Thomas R, Liu T, Schad A, Duenges B, David M, Hartmann EK.

Anaesthesia. 2015 Oct;70(10):1171-9. doi: 10.1111/anae.13154. Epub 2015 Jul 16.


Inhalation therapy with the synthetic TIP-like peptide AP318 attenuates pulmonary inflammation in a porcine sepsis model.

Hartmann EK, Ziebart A, Thomas R, Liu T, Schad A, Tews M, Moosmann B, Kamuf J, Duenges B, Thal SC, David M.

BMC Pulm Med. 2015 Feb 7;15:7. doi: 10.1186/s12890-015-0002-6.


Erratum to: surgical therapy of neuroendocrine neoplasm with hepatic metastasis: patient selection and prognosis.

Watzka FM, Fottner C, Miederer M, Schad A, Weber MM, Otto G, Lang H, Musholt TJ.

Langenbecks Arch Surg. 2015 Apr;400(3):359. doi: 10.1007/s00423-015-1294-y. No abstract available.


Surgical therapy of neuroendocrine neoplasm with hepatic metastasis: patient selection and prognosis.

Watzka FM, Fottner C, Miederer M, Schad A, Weber MM, Otto G, Lang H, Musholt TJ.

Langenbecks Arch Surg. 2015 Apr;400(3):349-58. doi: 10.1007/s00423-015-1277-z. Epub 2015 Feb 15. Erratum in: Langenbecks Arch Surg. 2015 Apr;400(3):359.


The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.

Thaler S, Thiede G, Hengstler JG, Schad A, Schmidt M, Sleeman JP.

Int J Cancer. 2015 Aug 1;137(3):686-97. doi: 10.1002/ijc.29404. Epub 2015 Jan 8.


Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion.

Sprinzl MF, Puschnik A, Schlitter AM, Schad A, Ackermann K, Esposito I, Lang H, Galle PR, Weinmann A, Heikenwälder M, Protzer U.

J Hepatol. 2015 Apr;62(4):863-70. doi: 10.1016/j.jhep.2014.11.011. Epub 2014 Nov 22.


Chronic heart damage following doxorubicin treatment is alleviated by lovastatin.

Henninger C, Huelsenbeck S, Wenzel P, Brand M, Huelsenbeck J, Schad A, Fritz G.

Pharmacol Res. 2015 Jan;91:47-56. doi: 10.1016/j.phrs.2014.11.003. Epub 2014 Nov 21.


Acute organ failure following the loss of anti-apoptotic cellular FLICE-inhibitory protein involves activation of innate immune receptors.

Gehrke N, Garcia-Bardon D, Mann A, Schad A, Alt Y, Wörns MA, Sprinzl MF, Zimmermann T, Menke J, Engstler AJ, Bergheim I, He YW, Galle PR, Schuchmann M, Schattenberg JM.

Cell Death Differ. 2015 May;22(5):826-37. doi: 10.1038/cdd.2014.178. Epub 2014 Oct 24.


Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial.

Thomaidis T, Maderer A, Formentini A, Bauer S, Trautmann M, Schwarz M, Neumann W, Kittner JM, Schad A, Link KH, Rey JW, Weinmann A, Hoffman A, Galle PR, Kornmann M, Moehler M.

J Exp Clin Cancer Res. 2014 Oct 2;33:83. doi: 10.1186/s13046-014-0083-8.


Low tidal volume pressure support versus controlled ventilation in early experimental sepsis in pigs.

Ziebart A, Hartmann EK, Thomas R, Liu T, Duenges B, Schad A, Bodenstein M, Thal SC, David M.

Respir Res. 2014 Sep 6;15:101. doi: 10.1186/s12931-014-0101-6.


VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Thomaidis T, Maderer A, Al-Batran SE, Kany J, Pauligk C, Steinmetz K, Schad A, Hofheinz R, Schmalenberg H, Homann N, Galle PR, Moehler M.

BMC Cancer. 2014 Jul 1;14:476. doi: 10.1186/1471-2407-14-476.


[Pleural effusion cytology of asbestos-associated malignant mesothelioma and lung carcinoma in the diagnosis of occupational diseases by the statutory accident insurance funds].

Biesterfeld S, Schramm M, Schad A, Pomjanski N.

Pneumologie. 2014 Apr;68(4):270-6. doi: 10.1055/s-0034-1365157. Epub 2014 Mar 10. German.


Phenotypic variability and risk of malignancy in SDHC-linked paragangliomas: lessons from three unrelated cases with an identical germline mutation (p.Arg133*).

Bickmann JK, Sollfrank S, Schad A, Musholt TJ, Springer E, Miederer M, Bartsch O, Papaspyrou K, Koutsimpelas D, Mann WJ, Weber MM, Lackner KJ, Rossmann H, Fottner C.

J Clin Endocrinol Metab. 2014 Mar;99(3):E489-96. doi: 10.1210/jc.2013-3486. Epub 2014 Jan 1.


[Drug-induced liver injury with an autoimmune phenotype following anti-TNF Therapy - presentation of cases and review of literature].

Rösner S, Schad A, Kittner J, Rahman F, Wörns MA, Schuchmann M, Galle PR, Schattenberg JM.

Z Gastroenterol. 2014 Jan;52(1):58-63. doi: 10.1055/s-0033-1356224. Epub 2014 Jan 13. Review. German.


High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer.

Oue N, Anami K, Schetter AJ, Moehler M, Okayama H, Khan MA, Bowman ED, Mueller A, Schad A, Shimomura M, Hinoi T, Aoyagi K, Sasaki H, Okajima M, Ohdan H, Galle PR, Yasui W, Harris CC.

Int J Cancer. 2014 Apr 15;134(8):1926-34. doi: 10.1002/ijc.28522. Epub 2013 Nov 8.


Diabetic liver injury from streptozotocin is regulated through the caspase-8 homolog cFLIP involving activation of JNK2 and intrahepatic immunocompetent cells.

Kohl T, Gehrke N, Schad A, Nagel M, Wörns MA, Sprinzl MF, Zimmermann T, He YW, Galle PR, Schuchmann M, Schattenberg JM.

Cell Death Dis. 2013 Jul 4;4:e712. doi: 10.1038/cddis.2013.228.


Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinoma.

Lautem A, Heise M, Gräsel A, Hoppe-Lotichius M, Weiler N, Foltys D, Knapstein J, Schattenberg JM, Schad A, Zimmermann A, Otto G, Lang H, Galle PR, Schuchmann M, Zimmermann T.

Int J Oncol. 2013 Apr;42(4):1297-304. doi: 10.3892/ijo.2013.1840. Epub 2013 Feb 22.


Resection strategies for neuroendocrine pancreatic neoplasms.

Watzka FM, Laumen C, Fottner C, Weber MM, Schad A, Lang H, Musholt TJ.

Langenbecks Arch Surg. 2013 Mar;398(3):431-40. doi: 10.1007/s00423-012-1024-7. Epub 2012 Nov 11.


The lipid lowering drug lovastatin protects against doxorubicin-induced hepatotoxicity.

Henninger C, Huelsenbeck J, Huelsenbeck S, Grösch S, Schad A, Lackner KJ, Kaina B, Fritz G.

Toxicol Appl Pharmacol. 2012 May 15;261(1):66-73.


Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP.

Schattenberg JM, Nagel M, Kim YO, Kohl T, Wörns MA, Zimmermann T, Schad A, Longerich T, Schuppan D, He YW, Galle PR, Schuchmann M.

Am J Physiol Gastrointest Liver Physiol. 2012 Aug 15;303(4):G498-506. doi: 10.1152/ajpgi.00525.2011. Epub 2012 Jun 14.


Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance.

Heise M, Lautem A, Knapstein J, Schattenberg JM, Hoppe-Lotichius M, Foltys D, Weiler N, Zimmermann A, Schad A, Gründemann D, Otto G, Galle PR, Schuchmann M, Zimmermann T.

BMC Cancer. 2012 Mar 22;12:109. doi: 10.1186/1471-2407-12-109.


RASSF1A inhibits estrogen receptor alpha expression and estrogen-independent signalling: implications for breast cancer development.

Thaler S, Schmidt M, Schad A, Sleeman JP.

Oncogene. 2012 Nov 22;31(47):4912-22. doi: 10.1038/onc.2011.658. Epub 2012 Jan 23.


Rac1-regulated endothelial radiation response stimulates extravasation and metastasis that can be blocked by HMG-CoA reductase inhibitors.

Hamalukic M, Huelsenbeck J, Schad A, Wirtz S, Kaina B, Fritz G.

PLoS One. 2011;6(10):e26413. doi: 10.1371/journal.pone.0026413. Epub 2011 Oct 19.


Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity.

Huelsenbeck J, Henninger C, Schad A, Lackner KJ, Kaina B, Fritz G.

Cell Death Dis. 2011 Aug 11;2:e190. doi: 10.1038/cddis.2011.65.


[Achalasia in a patient with HIV/HCV coinfection: detection of HCV in the esophageal tissue].

Gockel HR, Gockel I, Drescher DG, Müller H, Schad A, Kittner JM, Rossmann H, Lang H.

Chirurg. 2011 Nov;82(11):1021-6. doi: 10.1007/s00104-011-2140-6. German.


Supplemental Content

Support Center